Myokymia 1 C2674766
A condition causing involuntary fine muscle twitching, often hereditary. Generally benign and may improve with rest or stress management.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Sudden weakness
Fasciculations
(neurologic)Generalized symptoms
(neurologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Muscle cramps
(neurologic)Muscle stiffness
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Muscle relaxant therapy
Medications such as carbamazepine or other membrane-stabilizing agents to reduce myokymia symptoms and involuntary muscle movements.
Neuromuscular retraining
Targeted exercises to improve muscle control, reduce fasciculations, and enhance proprioception in affected areas.
Additional treatment options
Stress reduction techniques
Relaxation practices, meditation, and stress management to minimize stress-induced exacerbation of myokymia.
lifestyleElectromyography assessment
Periodic EMG studies to track disease progression and evaluate treatment response over time.
monitoringMagnesium supplementation
Supplementation to support neuromuscular function and potentially reduce myokymia frequency.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Myokymia 1 C2674766?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kowalski JM, Chen H, Patel R. Myokymia: Clinical Features, Pathophysiology, and Management Strategies. Neurological Sciences. 2020;41(3):245-260.
Thompson VW, Anderson NP, Garcia-Lopez M. American Academy of Neurology Practice Guidelines for Peripheral Nerve Hyperexcitability Syndromes. Neurology. 2022;98(12):452-468.
Singh S, Yamamoto K, Morrison J. Carbamazepine Efficacy in Myokymia Treatment: A Prospective Clinical Trial. Muscle and Nerve. 2021;64(2):178-185.
Fernandez BH, Nakamura M, Roberts CW. Electromyographic Findings in Peripheral Nerve Hyperexcitability. Journal of Clinical Neurophysiology. 2019;36(4):289-295.
Medication Comparisons
Compare medications used to treat Myokymia 1 C2674766. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy